CFTR and cystic fibrosis: Emerging data suggest that CFTR modulator therapies, such as elexacaftor–tezacaftor–ivacaftor, may partially restore microbial diversity and reduce pathogen load, potentially interrupting the typical trajectory of microbial succession in CF airways [35,49].